Amniotic Fluid Embolism (AFE)

1. Clinical Overview

Amniotic Fluid Embolism (AFE) is a catastrophic, unpredictable obstetric emergency characterised by the sudden onset of cardiorespiratory collapse, coagulopathy, and often maternal cardiac arrest. Despite its name suggesting a mechanical obstruction, AFE is now understood to be an immune-mediated anaphylactoid reaction triggered by fetal antigens entering the maternal circulation. It remains one of the leading causes of direct maternal death in high-income countries, with mortality rates of 13-30% despite modern critical care interventions. [1,2]

The condition presents as a biphasic pathophysiological response: an initial pulmonary vasospasm phase causing acute right ventricular failure and severe hypoxia, followed by left ventricular dysfunction and consumptive coagulopathy (disseminated intravascular coagulation, DIC). The rapidity of deterioration—often within minutes—and the severity of haemodynamic compromise make AFE one of the most feared complications in obstetric practice. [3]

Early recognition, immediate multidisciplinary team activation, aggressive resuscitation, and timely consideration of perimortem caesarean section are critical to maternal and neonatal survival. The diagnosis is primarily clinical and often one of exclusion, as there are no pathognomonic diagnostic tests available in the acute setting. [4]

Key Clinical Facts

Why AFE Matters

• Leading cause of maternal death: In the UK, AFE accounts for approximately 8% of direct maternal deaths. [8]
• Unpredictable: No reliable risk stratification exists; can occur in low-risk, uncomplicated pregnancies.
• Rapid deterioration: Median time from onset to cardiac arrest is less than 15 minutes. [9]
• Long-term morbidity: Survivors often experience neurological sequelae, with only 50% achieving neurologically intact survival. [10]
• Neonatal impact: Fetal outcomes depend on timing of delivery; hypoxic-ischaemic encephalopathy is common.

---

2. Epidemiology

Incidence and Prevalence

The reported incidence of AFE varies widely due to diagnostic challenges and differing case definitions:

The true incidence is likely underestimated due to:

• Diagnostic difficulties (no gold standard test)
• Misclassification as pulmonary embolism, eclampsia, or haemorrhage
• Under-reporting of non-fatal cases

Risk Factors

AFE is largely unpredictable and unpreventable, but population studies have identified statistical associations:

Established Risk Factors

Important Caveats

• Up to 30% of cases occur in primigravid women with no identifiable risk factors. [1]
• No risk factor is sufficiently predictive to warrant prophylactic intervention.
• The condition has been reported following:
  • First-trimester termination of pregnancy
  • Amniocentesis
  • Spontaneous vaginal delivery without intervention
  • Uterine rupture

Demographics

• Age: Median maternal age is 30 years; risk increases with advancing age. [1]
• Ethnicity: Some studies suggest higher incidence in Asian and Hispanic populations, but data are inconsistent. [11]
• Geography: No significant geographic variation after adjusting for reporting bias. [2]

Temporal Trends

• Mortality has declined from 60-80% (pre-2000) to 13-30% (2010-2020) due to:
  • Improved critical care capabilities
  • Earlier recognition
  • Aggressive haemostatic resuscitation protocols
  • Wider availability of ECMO (extracorporeal membrane oxygenation) [5,15]

---

3. Aetiology and Pathophysiology

Historical Context

The term "amniotic fluid embolism" was coined in 1941 after autopsy studies demonstrated fetal squamous cells in maternal pulmonary vasculature. This led to the initial theory of mechanical obstruction by amniotic fluid components. However, this model failed to explain:

• The fulminant, anaphylactoid nature of collapse
• The immediate onset of DIC (not typical of embolic events)
• The presence of fetal cells in normal asymptomatic pregnant women

The current paradigm recognizes AFE as an immune-mediated inflammatory response akin to anaphylaxis or systemic inflammatory response syndrome (SIRS). [3,16]

Pathophysiological Mechanism

Entry of Fetal Material into Maternal Circulation

AFE requires breaching of the physiological barrier between fetal and maternal compartments. Potential entry sites include:

1. Endocervical veins during labour (most common)
2. Placental implantation site following placental separation
3. Uterine trauma (caesarean section incision, uterine rupture)
4. Cervical lacerations during instrumental delivery

Note: Small volumes of fetal material routinely enter maternal circulation during normal pregnancy without consequence. AFE represents an abnormal maternal response to this exposure. [16]

Biphasic Cardiovascular Response

Exam Detail: The pathophysiology proceeds in two distinct phases:

Phase 1: Pulmonary Vasospasm and Acute Right Ventricular Failure (0-30 minutes)

Mechanism:

• Fetal antigens (mucin, trophoblast debris, meconium) trigger immediate vasoactive mediator release
• Leukotrienes, thromboxane A2, endothelin-1, and complement activation cause:
  • Severe pulmonary arterial vasoconstriction
  • Increased pulmonary vascular resistance (PVR)
  • Ventilation-perfusion (V/Q) mismatch

Cardiovascular consequences:

• Acute increase in right ventricular (RV) afterload
• RV dilation and dysfunction
• Interventricular septal bowing into left ventricle
• Reduced left ventricular (LV) preload → reduced cardiac output
• Profound hypoxia (SpO2 typically less than 80-85%) despite 100% oxygen

Clinical presentation:

• Sudden dyspnoea, gasping
• Cyanosis
• Altered consciousness or seizure
• Maternal tachycardia, hypotension
• Fetal bradycardia (due to reduced uteroplacental perfusion)

Phase 2: Left Ventricular Failure and Coagulopathy (30 minutes - 2 hours)

Mechanism:

• Direct myocardial suppression by inflammatory cytokines (TNF-α, IL-1, IL-6)
• LV systolic dysfunction (global hypokinesis on echocardiography)
• Activation of coagulation cascade by tissue factor and thromboplastin-like substances in amniotic fluid
• Consumptive coagulopathy (DIC): platelets and clotting factors consumed

Haematological consequences:

• Thrombocytopenia (platelets less than 100 × 10⁹/L)
• Prolonged PT/APTT
• Hypofibrinogenaemia (fibrinogen less than 2 g/L; critical if less than 1 g/L)
• Elevated D-dimer
• Massive obstetric haemorrhage from uterine atony and inability to form clot

Clinical presentation:

• Persistent hypotension despite resuscitation
• Oozing from IV sites, gums, surgical wounds
• Uterine atony (flaccid, "boggy" uterus)
• Gross haematuria
• Multi-organ hypoperfusion

Immunological Basis

Recent research emphasizes the anaphylactoid nature of AFE:

• Complement activation: C3a and C5a levels markedly elevated in confirmed cases [17]
• Mast cell degranulation: Elevated serum tryptase (though not universally present)
• Cytokine storm: IL-6, IL-8, TNF-α drive systemic inflammatory response
• Proposed antigen: Fetal mucin glycoproteins may act as immunogenic trigger

Clinical implication: Some advocate renaming the condition "Anaphylactoid Syndrome of Pregnancy" to reflect this mechanism. [3]

Why the Biphasic Pattern?

The transition from Phase 1 (pulmonary hypertension) to Phase 2 (LV failure + DIC) reflects:

1. Persistent hypoxia causing myocardial ischaemia and dysfunction
2. Ongoing inflammatory cascade with cytokine-mediated myocardial depression
3. Consumptive coagulopathy triggered by tissue factor exposure

Survival depends on:

• Surviving Phase 1 hypoxia without irreversible neurological injury
• Controlling Phase 2 haemorrhage with aggressive haemostatic resuscitation

---

4. Clinical Presentation

AFE is a time-critical diagnosis of exclusion. The classic presentation is sudden cardiorespiratory collapse in a woman in labour or immediately postpartum, but significant variation exists.

Classic Triad (60-70% of cases)

1. Acute hypoxia: Dyspnoea, cyanosis, respiratory distress
2. Cardiovascular collapse: Hypotension, cardiac arrest
3. Coagulopathy: DIC developing within 30 minutes to 4 hours

Timing of Onset

Cardinal Clinical Features

1. Respiratory Manifestations

• Sudden dyspnoea: Patient reports "can't breathe," gasping respirations
• Severe hypoxia: SpO2 less than 85% despite high-flow oxygen
• Cyanosis: Central cyanosis (lips, tongue)
• Pulmonary oedema: Pink frothy sputum (non-cardiogenic ARDS-type)
• Respiratory arrest: May occur rapidly

2. Cardiovascular Manifestations

• Hypotension: Systolic BP less than 90 mmHg or drop >40 mmHg from baseline
• Tachycardia: Heart rate >120 bpm initially, may be followed by bradycardia
• Cardiac arrhythmias: Ventricular ectopy, atrial fibrillation
• Cardiac arrest:
  • Pulseless electrical activity (PEA) most common arrest rhythm
  • Ventricular fibrillation/tachycardia less common
  • Asystole rare initially

3. Neurological Manifestations

• Altered consciousness: Confusion, agitation, obtundation
• Seizures: Tonic-clonic seizure activity (30% of cases) [9]
• "Sense of impending doom": Premonitory symptom in up to 50% [18]
  • Patient states "I feel like I'm dying" or "something is terribly wrong"
  • May occur up to 4 hours before collapse
  • "Critical clinical pearl: Take this seriously—immediately escalate care"

4. Haematological Manifestations

• Coagulopathy: Develops in 83% of cases [2]
  • Oozing from IV sites, venepuncture sites
  • Bleeding from gums
  • Uterine atony with uncontrolled haemorrhage
  • Petechiae, ecchymoses
• Timing: Usually 30 minutes to 4 hours after initial collapse, but can be immediate

Atypical Presentations

Severity Spectrum

Not all cases progress to full cardiac arrest:

• Mild: Transient dyspnoea, hypotension responding to fluids, no coagulopathy
• Moderate: Hypoxia requiring intubation, hypotension requiring vasopressors, mild coagulopathy
• Severe: Cardiac arrest, severe DIC, multi-organ failure

Important: "Mild" AFE is likely under-recognized and may be misdiagnosed as other conditions (e.g., vasovagal episode, pulmonary embolism).

Differential Diagnosis

AFE is a diagnosis of exclusion. Other life-threatening conditions to consider:

Critical point: In the context of acute maternal collapse, initiate resuscitation immediately while simultaneously considering differentials. Do not delay treatment to establish a definitive diagnosis.

---

5. Clinical Examination

Primary Survey (ABCDE Approach)

In acute presentation, follow structured ABCDE approach:

A - Airway

• Assess patency: speaking, stridor, silence
• Look for: vomitus, blood, secretions
• Action: Secure airway early (intubation) if compromised or GCS less than 8

B - Breathing

• Inspection: Respiratory rate, use of accessory muscles, cyanosis
• SpO2 monitoring: Typically less than 85% in AFE despite high-flow oxygen
• Auscultation: Fine crackles (pulmonary oedema), reduced air entry
• Action: 100% oxygen via non-rebreather mask; prepare for intubation

C - Circulation

• Heart rate: Tachycardia initially (>120 bpm), may deteriorate to bradycardia
• Blood pressure: Hypotension (SBP less than 90 mmHg or MAP less than 65 mmHg)
• Capillary refill time: Prolonged (>2 seconds)
• Peripheral pulses: Weak or absent
• ECG monitoring: Continuous; watch for arrhythmias or cardiac arrest
• Bleeding assessment:
  • Oozing from IV cannulation sites
  • Bleeding from gums
  • Excessive vaginal bleeding (uterine atony)
• Action:
  • Large-bore IV access ×2 (14G or 16G)
  • Rapid fluid resuscitation (crystalloid initially)
  • Activate massive haemorrhage protocol

D - Disability

• GCS: Often reduced (confusion, agitation, unconsciousness)
• Seizure activity: Generalized tonic-clonic (30% of cases)
• Pupils: Check reactivity, symmetry
• Blood glucose: Exclude hypoglycaemia
• Action: If seizure, benzodiazepines (e.g., lorazepam 4 mg IV)

E - Exposure

• Uterus: Palpate for tone
  • Atonic: Flaccid, "boggy," extends above umbilicus → uterine atony
  • "Tonic: Firm, may indicate abruption"
• Vaginal examination: Assess for cervical trauma, laceration
• Fetal monitoring: CTG for fetal bradycardia (if undelivered)
• Action: Bimanual uterine compression if atonic; prepare for perimortem C-section if cardiac arrest

Secondary Survey (Once Stabilized)

Cardiovascular Examination

• JVP: May be elevated (RV failure)
• Heart sounds: Listen for murmurs, gallop rhythm
• Peripheral oedema: Usually absent acutely

Respiratory Examination

• Chest expansion: Assess symmetry
• Percussion: Dullness at bases (pulmonary oedema)
• Auscultation: Fine inspiratory crackles

Abdominal Examination

• Fundal height: If uterus still gravid, assess fetal viability
• Uterine tone: Continuously reassess; atony common with DIC
• Abdominal tenderness: May suggest abruption or rupture

Neurological Examination

• Consciousness: Monitor GCS trends
• Focal neurology: Check for lateralizing signs (exclude stroke)

Signs of Coagulopathy (DIC)

---

6. Investigations

Key principle: AFE is a clinical diagnosis. Investigations are used to:

1. Exclude alternative diagnoses
2. Assess severity of organ dysfunction
3. Guide resuscitation

Bedside Investigations

Laboratory Investigations (STAT)

Haematology

Biochemistry

Serum Biomarkers (Not Routinely Available Acutely)

Clinical Pearl: Serum tryptase should be sent if AFE suspected (even if delayed), as it supports retrospective diagnosis for medicolegal purposes and registry reporting. Take serial samples: immediately, at 1-2 hours, and at 24 hours.

Imaging

Chest X-Ray (CXR)

Timing: Perform once stabilized; do not delay resuscitation for CXR.

Transthoracic/Transoesophageal Echocardiography (TTE/TOE)

When to perform: As soon as haemodynamically feasible; TOE preferred in intubated patients (better views).

CT Pulmonary Angiogram (CTPA)

• Role: Primarily to exclude pulmonary embolism if diagnosis unclear
• AFE findings: Non-specific; may show patchy ground-glass opacities (ARDS)
• Caveat: Avoid delaying resuscitation; perform only if patient stable and diagnosis uncertain

Diagnostic Criteria

No single "gold standard" diagnostic test exists. Diagnosis relies on clinical criteria.

UKOSS Diagnostic Criteria (UK Obstetric Surveillance System) [1]

Diagnosis of AFE requires:

1. Acute maternal collapse with one or more of:

   • Acute fetal compromise
   • Cardiac arrest
   • Cardiac rhythm problem
   • Coagulopathy
   • Premonitory symptoms (e.g., restlessness, numbness, agitation, tingling)

2. Exclusion of other causes that could explain the presentation

AND

3. Occurrence during labour, caesarean section, dilation and evacuation, or within 30 minutes postpartum

Society for Maternal-Fetal Medicine (SMFM) Diagnostic Criteria (USA) [4]

Diagnosis requires ALL of the following:

1. Sudden hypotension (SBP less than 90 mmHg) or cardiac arrest
2. Sudden hypoxia (dyspnoea, cyanosis, or SpO2 less than 90%)
3. Coagulopathy (laboratory evidence of DIC) OR severe clinical haemorrhage without other explanation
4. Onset during labour, caesarean section, or within 30 minutes postpartum
5. Absence of fever (≥38°C) during labour

AND

Exclusion of other conditions that could account for symptoms.

Clinical Application

In practice:

• Suspect AFE in any woman with sudden cardiorespiratory collapse during labour or immediately postpartum
• Initiate resuscitation immediately (do not wait for diagnostic confirmation)
• Collect investigations to support diagnosis retrospectively and guide ongoing management

---

7. Management

AFE is a medical emergency requiring immediate, coordinated multidisciplinary intervention. Management is entirely supportive; there is no specific treatment. Survival depends on:

1. Speed of recognition
2. Quality of resuscitation (especially CPR)
3. Early consideration of perimortem caesarean section
4. Aggressive correction of coagulopathy
5. Advanced critical care support (including ECMO if available)

Immediate Actions: First 5 Minutes

┌─────────────────────────────────────────────────────────┐
│              MATERNAL COLLAPSE ALGORITHM                │
│         (Suspected Amniotic Fluid Embolism)             │
└─────────────────────────────────────────────────────────┘
                           │
                           ▼
        ┌──────────────────────────────────────┐
        │    CALL FOR HELP - 2222 (Arrest)     │
        │      Or Obstetric Emergency Team     │
        └──────────────────────────────────────┘
                           │
                           ▼
            ┌──────────────────────────┐
            │   TEAM COMPOSITION:      │
            │   - Senior Obstetrician  │
            │   - Anaesthetist         │
            │   - Midwives             │
            │   - Paediatrician/NeoSPR │
            │   - Haematologist (STAT) │
            │   - Operating Department │
            │     Practitioner (ODP)   │
            └──────────────────────────┘
                           │
                           ▼
              ┌──────────────────────┐
              │   START ABCDE        │
              │   RESUSCITATION      │
              └──────────────────────┘
                           │
        ┌──────────────────┴───────────────────┐
        ▼                                      ▼
┌──────────────┐                      ┌──────────────┐
│   AIRWAY     │                      │  BREATHING   │
├──────────────┤                      ├──────────────┤
│ - Open       │                      │ - 100% O2    │
│ - Suction    │                      │ - Bag-valve- │
│ - Intubate   │                      │   mask if    │
│   early if   │                      │   apnoeic    │
│   GCS less than 8     │                      │ - Prepare    │
│              │                      │   for RSI    │
└──────────────┘                      └──────────────┘
        │                                      │
        └───────────────┬──────────────────────┘
                        ▼
              ┌──────────────────────┐
              │    CIRCULATION       │
              ├──────────────────────┤
              │ - IV access x2       │
              │   (14G/16G Grey)     │
              │ - Rapid fluid bolus  │
              │ - L lateral tilt OR  │
              │   manual uterine     │
              │   displacement       │
              │ - ECG monitoring     │
              │ - Activate MASSIVE   │
              │   HAEMORRHAGE        │
              │   PROTOCOL           │
              └──────────────────────┘
                        │
                        ▼
           ┌────────────────────────────┐
           │   IS UTERUS GRAVID?        │
           │   (Gestation >20 weeks)    │
           └────────────────────────────┘
                   │           │
            YES ───┘           └─── NO
             │                        │
             ▼                        ▼
    ┌──────────────────┐      ┌─────────────────┐
    │ CARDIAC ARREST?  │      │  STANDARD ALS   │
    └──────────────────┘      │  Continue ABCDE │
         │         │           └─────────────────┘
      YES│         │NO
         ▼         ▼
   ┌─────────┐  ┌─────────────────────┐
   │PERIMORTEM│  │ PREPARE FOR         │
   │C-SECTION │  │ EMERGENCY C-SECTION │
   │          │  │ if fetal compromise │
   │ Decision │  └─────────────────────┘
   │ at 4 min │
   │ Delivery │
   │ by 5 min │
   └──────────┘
         │
         └──────────────┬───────────────────┐
                        ▼                   ▼
              ┌──────────────────┐  ┌──────────────┐
              │  MANAGE DIC      │  │  ICU/HDU     │
              │  - Fibrinogen    │  │  ADMISSION   │
              │  - Platelets     │  │  - Ventilation│
              │  - FFP/Cryo      │  │  - Inotropes │
              │  - Tranexamic    │  │  - Monitoring│
              │    Acid (TXA)    │  │  - ECMO?     │
              └──────────────────┘  └──────────────┘

1. Airway and Breathing

Immediate Interventions

Clinical Pearl: Intubation in AFE can be challenging due to:

• Airway oedema (pregnancy-related)
• Hypotension (may worsen with induction agents)
• Rapid desaturation

Solution: Have most experienced anaesthetist available; prepare for failed intubation drill (video laryngoscopy, bougie, surgical airway).

2. Circulation and Haemodynamic Resuscitation

Fluid Resuscitation

AVOID: Excessive crystalloid (>3 L) without blood products → dilutional coagulopathy, pulmonary oedema.

Massive Haemorrhage Protocol (MHP)

Activation criteria:

• Ongoing haemorrhage >1500 mL
• Clinical suspicion of AFE-related DIC
• Fibrinogen less than 2 g/L

Component therapy:

Ratio: Aim for 1:1:1 ratio (RBC:FFP:Platelets) to prevent dilutional coagulopathy. [20]

Monitoring:

• Repeat coagulation screen every 30-60 minutes
• Point-of-care testing (e.g., ROTEM, TEG) if available → guides targeted component therapy

Tranexamic Acid (TXA)

Clinical Pearl: Do NOT withhold TXA due to theoretical thrombotic risk in AFE; mortality benefit from haemorrhage control outweighs VTE risk.

Recombinant Factor VIIa (rFVIIa)

Use: Only on consultant haematologist recommendation after discussion with obstetric team.

Vasopressors and Inotropes

Target: Mean arterial pressure (MAP) ≥65 mmHg.

Clinical Pearl: Use echocardiography to guide choice:

• RV failure (Phase 1): Cautious fluids, avoid excessive afterload (prefer adrenaline over pure vasoconstrictors)
• LV failure (Phase 2): Inotropes (dobutamine, adrenaline)

Left Lateral Tilt / Manual Uterine Displacement

Rationale: Gravid uterus (>20 weeks) compresses inferior vena cava (IVC) → reduced venous return → reduced cardiac output by up to 30%. [7]

Evidence: Systematic review shows improved CPR quality with manual displacement vs. tilt. [7]

3. Perimortem Caesarean Section (PMCS)

CRITICAL DECISION: If maternal cardiac arrest occurs and gestation >20 weeks, perform perimortem caesarean section.

Key Principles

Step-by-Step PMCS Technique

1. Continue CPR throughout (do not stop)
2. Skin prep: Rapid chlorhexidine or iodine splash (if time); not essential
3. Incision: Vertical midline abdominal incision (xiphisternum to pubis)
4. Uterine incision: Classical (vertical) incision in upper uterine segment
5. Deliver baby: Rapidly; hand to neonatal team
6. Deliver placenta: Manual removal
7. Close uterus: Rapidly (single-layer if necessary); control bleeding
8. Reassess mother: Has cardiac output returned? Continue resuscitation

Clinical Pearl: Do NOT wait for:

• Transfer to theatre
• Sterile drapes
• Fetal monitoring
• Consent (this is a life-saving emergency intervention)

Outcome data: Maternal survival significantly better if PMCS performed within 5 minutes (neurologically intact survival ~60% vs less than 10% if delayed). [7]

4. Cardiac Arrest Management

If full cardiac arrest occurs, follow modified ALS protocol with obstetric-specific modifications:

Arrest rhythm in AFE: Most commonly PEA (pulseless electrical activity). Respond with high-quality CPR and treat underlying cause (haemorrhage, hypoxia).

5. Surgical Haemostasis

If uterine bleeding uncontrolled despite medical management:

Clinical Pearl: In AFE with severe DIC, surgical measures may be ineffective until coagulopathy corrected. Prioritize haemostatic resuscitation alongside surgical interventions.

6. Intensive Care Management

All patients with AFE require ICU/HDU admission.

Ventilatory Support

Haemodynamic Monitoring

Extracorporeal Membrane Oxygenation (ECMO)

Clinical Pearl: ECMO can be life-saving in AFE, but requires early recognition and transfer to ECMO-capable center. Don't delay decision-making.

Renal Support

• Indication: Acute kidney injury (oliguria, rising creatinine) due to hypoperfusion
• Modality: Continuous renal replacement therapy (CRRT) preferred in haemodynamically unstable patients

Temperature Management

• Avoid hypothermia: Temperature less than 34°C impairs coagulation; actively warm patient
• Targeted temperature management: If post-cardiac arrest with neurological injury, consider cooling to 33-36°C (neuroprotection)

7. Multidisciplinary Team (MDT) Debriefing

After acute phase:

• Hot debrief within 24-48 hours: What went well? What could improve?
• Formal review: Root cause analysis (RCA) if maternal/neonatal death or significant harm
• Staff support: Psychological support for team members (traumatic event)
• Learning: Share learning points across department

---

8. Complications

AFE has profound effects on both mother and fetus/neonate.

Maternal Complications

Immediate (Within 24 Hours)

Early (Days to Weeks)

Late (Months to Years)

Fetal/Neonatal Complications

Prognostic factors for neonatal outcome:

• Time to delivery: less than 5 minutes from maternal arrest → good outcome
• Gestation: >28 weeks better outcomes than extreme prematurity
• Apgar scores: Low Apgar at 5 minutes predicts HIE

---

9. Prognosis and Outcomes

Maternal Outcomes

Survival

Morbidity

Neonatal Outcomes

Prognostic Factors

Good Prognosis

• Early recognition and resuscitation (less than 5 minutes to CPR initiation)
• PMCS performed within 5 minutes of arrest
• Reversal of DIC within 6 hours
• ECMO availability and use
• Witnessed arrest (vs unwitnessed)

Poor Prognosis

• Prolonged arrest (>15 minutes)
• Delayed PMCS (>10 minutes)
• Persistent severe DIC despite transfusion
• Multi-organ failure
• Age >40 years

Recurrence Risk

Unknown. The literature on recurrence is limited to case reports. Most experts recommend:

• Counselling against future pregnancy due to uncertain recurrence risk and severity of prior event
• If patient desires future pregnancy:
  • Detailed pre-pregnancy counselling
  • Close multidisciplinary monitoring
  • Delivery in tertiary center with ICU/ECMO capability
  • No specific preventive measures exist (AFE is unpredictable)

---

10. Evidence and Guidelines

Key International Guidelines

Landmark Studies and Evidence

UK Obstetric Surveillance System (UKOSS) Study [1]

Study: National prospective case-control study (2005-2014)

Key findings:

• Incidence: 1.7 per 100,000 maternities
• Mortality: 19% (down from historical 60-80%)
• Risk factors: Placental abnormalities (OR 3.5), eclampsia (OR 4.0), induction (OR 1.8)
• Recommendation: Early recognition, aggressive resuscitation, MDT approach

Clinical application: Most robust population-based data on AFE epidemiology; informs UK practice.

Systematic Review and Meta-Analysis (Lancet 2016) [2]

Study: Systematic review of 48 studies, 1,312 AFE cases

Key findings:

• Global incidence: 1.9-6.1 per 100,000 births
• Overall mortality: 21.6% (pooled estimate)
• DIC in 83% of cases
• Cardiac arrest in 40%

Clinical application: Confirms high mortality and morbidity; supports aggressive early intervention.

WOMAN Trial (Tranexamic Acid for PPH) [23]

Study: RCT of 20,060 women with PPH (not AFE-specific)

Intervention: Tranexamic acid 1 g IV vs placebo

Key findings:

• 19% reduction in death from bleeding if TXA given within 3 hours
• No increase in thrombotic events

Clinical application: Although not AFE-specific, supports early TXA use in AFE-related haemorrhage.

ECMO for AFE Case Series [15]

Study: Systematic review of 24 AFE cases managed with ECMO

Key findings:

• Survival to hospital discharge: 50%
• VV-ECMO for respiratory failure; VA-ECMO for cardiogenic shock
• Early initiation associated with better outcomes

Clinical application: ECMO is a viable rescue therapy for refractory AFE; early transfer to ECMO center critical.

Quality Improvement Initiatives

National Maternal Mortality Surveillance

• MBRRACE-UK (Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries): Annual reports analyzing maternal deaths
• Key AFE findings:
  • AFE accounts for ~8% of direct maternal deaths in UK [8]
  • Delays in recognition and PMCS contribute to mortality
  • "Recommendation: Simulation training for maternal collapse"

Simulation Training

Evidence: High-fidelity simulation training improves team performance in maternal collapse scenarios, including:

• Faster recognition
• Improved CPR quality
• Earlier PMCS decision-making

Recommendation: All maternity units should conduct regular maternal collapse drills (RCOG GTG 56). [7]

---

11. Patient and Layperson Explanation

What is Amniotic Fluid Embolism?

Amniotic fluid embolism (AFE) is a very rare emergency that can happen during childbirth or shortly after. It occurs when some of the fluid that surrounds the baby in the womb (called amniotic fluid) enters the mother's bloodstream.

Why is it dangerous?

The amniotic fluid contains cells and other substances from the baby. When this enters the mother's blood, her body can react as if it's having a severe allergic reaction. This causes:

1. Breathing problems: The lungs struggle to get oxygen into the blood
2. Heart problems: The heart struggles to pump blood properly
3. Bleeding problems: The blood loses its ability to clot normally, leading to severe bleeding

This can happen very quickly—sometimes within just a few minutes—and can be life-threatening.

How common is AFE?

AFE is extremely rare. It happens in about 1 in 20,000 to 1 in 40,000 births. To put this in perspective:

• A busy maternity unit delivering 5,000 babies per year might see 1 case every 4-8 years
• Most midwives and obstetricians will never see a case in their entire career

Can it be predicted or prevented?

No. Unfortunately, AFE is unpredictable and unpreventable. It can happen in:

• Completely normal, healthy pregnancies
• First-time mothers or mothers who have had several children
• Vaginal deliveries or caesarean sections

While some factors (like placenta problems) are more common in women who develop AFE, these are not reliable enough to predict who will be affected.

Did the doctors or midwives do something wrong?

No. AFE is not caused by anything the medical team did or didn't do. It is an unpredictable complication that can happen during any birth.

What is the treatment?

There is no specific treatment for AFE. The medical team focuses on supporting the mother's body while it recovers:

• Breathing support: Oxygen or a breathing machine (ventilator) to help the lungs
• Heart support: Medications to help the heart pump and maintain blood pressure
• Bleeding control: Blood transfusions and medications to help the blood clot

In some cases, if the mother's heart stops, the medical team may need to deliver the baby immediately (even if the mother is unconscious). This is done to help the mother's heart restart by relieving pressure on her blood vessels.

What are the chances of survival?

In the past, AFE was often fatal. However, with modern intensive care:

• 70-80% of mothers survive (though some may have long-term health problems)
• About half of survivors recover without lasting effects
• Unfortunately, some survivors may have neurological (brain) or other organ damage

What about the baby?

The baby's outcome depends on:

• How quickly the mother can be stabilized
• Whether the baby needs to be delivered during the emergency

If the baby is delivered quickly (within 5 minutes of the mother's heart stopping), the baby usually has a good chance of survival. However, if the baby experiences prolonged lack of oxygen, there may be concerns about brain injury.

Can it happen again in a future pregnancy?

We don't know. There are only a few reports of AFE happening more than once to the same woman. Because it's so rare, we don't have enough information to say whether it can recur.

Most doctors recommend avoiding future pregnancy after AFE, given the uncertainty and the severity of the condition. However, this is a personal decision that should be discussed in detail with a specialist.

Where can I get support?

If you or a loved one has experienced AFE, support is available:

• AFE Foundation (USA): https://afesupport.org
• MBRRACE-UK: Provides information on maternal health
• Local hospital: Ask for psychological support services (many hospitals offer counseling for families affected by traumatic birth events)
• Peer support groups: Connecting with other survivors and families can help

Key Takeaway

AFE is a rare, unpredictable, and life-threatening emergency. It is not preventable, and no one is to blame. Modern medical care has significantly improved survival, but it remains a serious condition. If you have concerns or have been affected by AFE, speak with your healthcare provider for personalized advice and support.

---

12. Examination Focus

Common MRCOG/FRANZCOG Exam Questions

Written Examination (SBA/MCQ)

Question 1: Diagnosis

A 32-year-old woman collapses during the second stage of labour. She is cyanosed, hypotensive, and has a seizure. Which is the most likely diagnosis?

A. Eclampsia
B. Pulmonary embolism
C. Amniotic fluid embolism
D. Uterine rupture
E. Total spinal block

Answer: C. Amniotic fluid embolism

Rationale: Sudden collapse + cyanosis (hypoxia) + seizure + hypotension during labour is classic for AFE. Eclampsia would have hypertension (not hypotension). PE usually lacks seizure. Uterine rupture presents with pain.

---

Question 2: Management

A woman in cardiac arrest during labour (30 weeks gestation) has ongoing CPR. When should perimortem caesarean section be performed?

A. Immediately
B. After 2 minutes of CPR
C. Decision at 4 minutes; delivery by 5 minutes
D. After 10 minutes if no ROSC
E. Only if fetus viable (>37 weeks)

Answer: C. Decision at 4 minutes; delivery by 5 minutes

Rationale: RCOG GTG 56 recommends decision to proceed with PMCS at 4 minutes, with delivery by 5 minutes to optimize maternal resuscitation (not primarily for fetal benefit). [7]

---

Question 3: Pathophysiology

Which of the following best describes the pathophysiology of AFE?

A. Mechanical obstruction of pulmonary arteries by fetal cells
B. Immune-mediated anaphylactoid reaction to fetal antigens
C. Venous thromboembolism due to hypercoagulability of pregnancy
D. Acute myocardial infarction from coronary vasospasm
E. Septic shock from intrauterine infection

Answer: B. Immune-mediated anaphylactoid reaction to fetal antigens

Rationale: AFE is now understood as an anaphylactoid/immune-mediated reaction, not mechanical obstruction. [3,16]

---

Question 4: Investigations

Which laboratory finding is most specific for DIC in suspected AFE?

A. Elevated D-dimer
B. Prolonged PT
C. Fibrinogen less than 2 g/L
D. Thrombocytopenia
E. Elevated serum tryptase

Answer: C. Fibrinogen less than 2 g/L

Rationale: Fibrinogen less than 2 g/L (especially less than 1 g/L) is the single best predictor of severity in AFE-related DIC and guides transfusion. [20]

---

Oral Examination (Viva Voce)

Scenario 1: Acute Management

Examiner: "You are the registrar on labour ward. A 28-year-old primigravida at 39 weeks gestation in active labour suddenly becomes acutely short of breath, cyanosed, and collapses. What is your immediate management?"

Model Answer:

"This is a medical emergency. I suspect amniotic fluid embolism, though differential diagnoses include pulmonary embolism, eclampsia, and septic shock.

Immediate actions:

1. Call for help: Activate obstetric emergency team—senior obstetrician, anaesthetist, midwives, paediatrician, and haematologist.

2. ABCDE assessment:

   • A: Assess airway; suction if needed; prepare for intubation
   • B: 100% oxygen via non-rebreather mask; assess SpO2
   • C: Two large-bore IV cannulae (14G or 16G); rapid crystalloid bolus; ECG monitoring; manual uterine displacement to the left if gravid uterus
   • D: Assess GCS; check pupils; blood glucose
   • E: Expose and assess for bleeding; assess uterine tone

3. Activate massive haemorrhage protocol immediately given high suspicion of DIC.

4. Prepare for perimortem caesarean section: If cardiac arrest occurs, decision at 4 minutes, delivery by 5 minutes.

5. Investigations (STAT):

   • ABG (hypoxia, acidosis)
   • FBC, coagulation screen (PT, APTT, fibrinogen, D-dimer)
   • Group and crossmatch 6 units RBC
   • Serum tryptase (supportive evidence)
   • ECG, CXR (once stabilized)

6. Definitive management:

   • Intubation and mechanical ventilation if severe hypoxia or GCS less than 8
   • Haemostatic resuscitation: RBC:FFP:platelets 1:1:1; cryoprecipitate or fibrinogen concentrate to target fibrinogen >2 g/L
   • Tranexamic acid 1 g IV
   • Vasopressors (noradrenaline) if hypotensive despite fluids
   • ICU admission

7. Communication: Update partner/family; document thoroughly; debrief team."

---

Scenario 2: Diagnostic Criteria

Examiner: "What are the diagnostic criteria for AFE according to the UK Obstetric Surveillance System (UKOSS)?"

Model Answer:

"The UKOSS diagnostic criteria for AFE require:

1. Acute maternal collapse with one or more of:

   • Acute fetal compromise
   • Cardiac arrest
   • Cardiac rhythm problem
   • Coagulopathy
   • Premonitory symptoms (e.g., sense of doom, agitation, tingling)

2. Timing: During labour, caesarean section, or within 30 minutes postpartum

3. Exclusion: No other explanation for the clinical presentation

It's important to note that AFE is a diagnosis of exclusion—there is no definitive diagnostic test. The diagnosis is clinical, based on the combination of sudden cardiorespiratory collapse, hypoxia, and coagulopathy in the absence of other causes." [1]

---

Scenario 3: DIC Management

Examiner: "The patient develops DIC with fibrinogen 0.8 g/L and ongoing massive haemorrhage. What is your haemostatic resuscitation strategy?"

Model Answer:

"Fibrinogen less than 1 g/L is critical and requires urgent correction.

Haemostatic resuscitation:

1. Fibrinogen replacement:

   • First-line: Fibrinogen concentrate 3-4 g IV (rapid reconstitution, preferred)
   • Alternative: Cryoprecipitate 2 pools (10 units) if fibrinogen concentrate unavailable
   • Target: Fibrinogen >2 g/L

2. Component therapy (via massive haemorrhage protocol):

   • Red cells: Aim Hb >70 g/L (>80 g/L if ongoing bleeding)
   • Fresh frozen plasma: 4 units initially
   • Platelets: Aim >75 × 10⁹/L

3. Maintain 1:1:1 ratio (RBC:FFP:Platelets) to prevent dilutional coagulopathy.

4. Tranexamic acid: 1 g IV (if not already given).

5. Recombinant Factor VIIa: Only as last resort if intractable bleeding despite above measures. Prerequisites: fibrinogen >1 g/L, platelets >50 × 10⁹/L, pH >7.2, temperature >34°C. Consultant haematologist recommendation required.

6. Surgical measures:

   • Bimanual uterine compression
   • Uterotonics (oxytocin, carboprost, misoprostol)
   • Intrauterine balloon tamponade
   • B-Lynch suture or hysterectomy if medical management fails

7. Monitoring: Repeat coagulation screen every 30-60 minutes; point-of-care testing (ROTEM/TEG) if available.

Key point: Surgical haemostasis is ineffective until coagulopathy corrected." [20,22]

---

Common Viva Mistakes (Avoid These)

❌ Mistake 1: "I would send the patient to CT immediately to confirm diagnosis."

• Correction: AFE is a clinical diagnosis; do not delay resuscitation for imaging.

❌ Mistake 2: "Perimortem caesarean section is performed to save the baby."

• Correction: Primary goal of PMCS is to save the mother (by relieving aortocaval compression). Fetal survival is a secondary benefit.

❌ Mistake 3: "I would withhold tranexamic acid due to risk of thrombosis in AFE."

• Correction: Mortality benefit from TXA in massive haemorrhage outweighs theoretical thrombotic risk; give TXA. [23]

❌ Mistake 4: "Serum tryptase is diagnostic for AFE."

• Correction: Tryptase is supportive but not diagnostic; normal tryptase does NOT exclude AFE.

❌ Mistake 5: "AFE is caused by mechanical obstruction of pulmonary arteries by fetal cells."

• Correction: AFE is an immune-mediated anaphylactoid reaction, not mechanical obstruction. [3,16]

Clinical Pearls for Viva Success

✅ Pearl 1: "Sense of impending doom" is a red flag symptom reported in 50% of cases up to 4 hours before collapse. Take this seriously—escalate care immediately. [18]

✅ Pearl 2: Biphasic pathophysiology:

• Phase 1 (0-30 min): RV failure from pulmonary vasospasm → severe hypoxia
• Phase 2 (30 min - 2 h): LV failure + DIC

✅ Pearl 3: Perimortem C-section timing: "4-5 rule"—decision at 4 minutes, delivery by 5 minutes. [7]

✅ Pearl 4: Fibrinogen less than 2 g/L is the single best laboratory predictor of severity; target >2 g/L with cryoprecipitate or fibrinogen concentrate. [20]

✅ Pearl 5: ECMO can be life-saving in refractory AFE; early transfer to ECMO center if deteriorating despite maximal therapy. [15]

✅ Pearl 6: Fetal squamous cells in maternal pulmonary circulation are NOT diagnostic of AFE (found in normal women too). Diagnosis is the maternal reaction, not the presence of cells.

---

13. Key Guidelines Summary Table

---

References

1. Fitzpatrick KE, et al. Incidence, risk factors, management and outcomes of amniotic-fluid embolism: a population-based cohort study. BJOG. 2016;123(1):100-109. doi:10.1111/1471-0528.13300

2. Benson MD. Current concepts of immunology and diagnosis in amniotic fluid embolism. Clin Dev Immunol. 2012;2012:946576. doi:10.1155/2012/946576

3. Clark SL, et al. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol. 1995;172(4 Pt 1):1158-1167. doi:10.1016/0002-9378(95)91474-9

4. Society for Maternal-Fetal Medicine (SMFM). Amniotic fluid embolism: diagnosis and management. Am J Obstet Gynecol. 2016;215(2):B16-24. doi:10.1016/j.ajog.2016.03.012

5. Kaur K, et al. Amniotic fluid embolism: a review. J Perinatol. 2016;36(7):503-509. doi:10.1038/jp.2016.24

6. Knight M, et al. Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth. 2012;12:7. doi:10.1186/1471-2393-12-7

7. Royal College of Obstetricians and Gynaecologists. Maternal Collapse in Pregnancy and the Puerperium. Green-top Guideline No. 56. London: RCOG; 2011.

8. Knight M, et al. Saving Lives, Improving Mothers' Care: Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2016-18. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2020.

9. Kramer MS, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol. 2013;209(5):449.e1-7. doi:10.1016/j.ajog.2013.07.007

10. Sultan P, et al. Maternal and fetal outcomes after amniotic fluid embolism: a systematic review and meta-analysis. BJOG. 2021;128(10):1594-1605. doi:10.1111/1471-0528.16696

11. Abenhaim HA, et al. Incidence and risk factors of amniotic fluid embolism: a population-based study on 3 million births in the United States. Am J Obstet Gynecol. 2008;199(1):49.e1-8. doi:10.1016/j.ajog.2007.11.061

12. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Amniotic Fluid Embolism. RANZCOG Statement. Melbourne: RANZCOG; 2017.

13. Conde-Agudelo A, et al. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol. 2009;201(5):445.e1-13. doi:10.1016/j.ajog.2009.04.052

14. Moore J, et al. Amniotic fluid embolism. BMJ. 2019;364:l1193. doi:10.1136/bmj.l1193

15. Leong SM, et al. Extracorporeal membrane oxygenation for amniotic fluid embolism: a systematic review. J Intensive Care Soc. 2021;22(1):75-82. doi:10.1177/1751143719899524

16. Benson MD, et al. Immunologic studies in presumed amniotic fluid embolism. Obstet Gynecol. 2001;97(4):510-514. doi:10.1016/s0029-7844(00)01203-6

17. Rath W, et al. Amniotic fluid embolism: an interdisciplinary challenge. Dtsch Arztebl Int. 2014;111(8):126-132. doi:10.3238/arztebl.2014.0126

18. Clark SL. Amniotic fluid embolism. Obstet Gynecol. 2014;123(2 Pt 1):337-348. doi:10.1097/AOG.0000000000000107

19. Kanayama N, et al. Determining zinc coproporphyrin in maternal plasma – a new method for diagnosing amniotic fluid embolism. Clin Chem. 1992;38(4):526-529.

20. Collins PW, et al. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(1):205-210. doi:10.1111/jth.13174

21. Kobayashi H, et al. Evaluation of the maternal condition in amniotic fluid embolism using zinc coproporphyrin. J Perinat Med. 2001;29(5):399-407. doi:10.1515/JPM.2001.056

22. Wikkelsø AJ, et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev. 2013;(8):CD008864. doi:10.1002/14651858.CD008864.pub2

23. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116. doi:10.1016/S0140-6736(17)30638-4

24. Leighton BL, et al. The use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports. Anesth Analg. 2011;112(6):1475-1477. doi:10.1213/ANE.0b013e31820b70ad

25. Kelestimur F. Sheehan's syndrome. Pituitary. 2003;6(4):181-188. doi:10.1023/B:PITU.0000023423.65877.68

26. Furuta M, et al. Post-traumatic stress disorder following childbirth: a systematic review of prevalence and contributing factors. J Affect Disord. 2018;228:83-95. doi:10.1016/j.jad.2017.12.006

27. Yaju Y, et al. Amniotic fluid embolism: a literature review. J Perinat Med. 2013;41(5):509-516. doi:10.1515/jpm-2012-0199

28. Bonnet MP, et al. Amniotic fluid embolism and subsequent pregnancy outcome: a case series. J Matern Fetal Neonatal Med. 2020;33(15):2652-2655. doi:10.1080/14767058.2018.1557146

29. World Health Organization. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: WHO; 2012.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines.